Education
About Us
Working with TipRanks
Follow Us
Syndax Pharmaceuticals Inc. (SNDX)
NASDAQ:SNDX
SNDX Stock Chart & Stats
$22.07
$0.12(0.87%)
At close: 4:00 PM EST
$22.07
$0.12(0.87%)
Day’s Range― - ―
52-Week Range$8.58 - $22.73
Previous CloseN/A
Volume201.89K
Average Volume (3M)1.22M
Market Cap
$1.95B
Enterprise Value$2.16B
Total Cash (Recent Filing)$394.07M
Total Debt (Recent Filing)$346.48M
Price to Earnings (P/E)―
Beta1.08
Next Earnings
May 11, 2026EPS Estimate
-0.58Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.78
Shares Outstanding88,200,600
10 Day Avg. Volume1,282,771
30 Day Avg. Volume1,220,343
Financial Highlights & Ratios
PEG Ratio0.55
Price to Book (P/B)28.16
Price to Sales (P/S)10.56
P/FCF Ratio-5.63
Enterprise Value/Market Cap1.11
Enterprise Value/Revenue12.52
Enterprise Value/Gross Profit13.05
Enterprise Value/Ebitda-9.78
Forecast
1Y Price Target
$41.67Price Target Upside88.81% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering7
EPS Forecast (FY)-1.63
Revenue Forecast (FY)$362.43M
Bulls Say, Bears Say
Bulls Say
Clinical CatalystsTopline results from the Phase II axatilimab trial in idiopathic pulmonary fibrosis and multiple pivotal studies in AML and cGVHD could materially enlarge the addressable market if proof of concept is demonstrated.
Commercial AdoptionRevuforj's rising prescriptions and broadened formulary coverage in newly approved AML subgroups support expanding use in maintenance and post‑transplant treatment settings, underpinning revenue growth.
Financial RunwayA substantial cash balance and revenue sharing from Niktimvo sales lower near‑term financing risk and provide operational runway to advance commercialization and clinical programs.
Bears Say
Competitive ThreatA rival menin inhibitor with a cleaner safety profile and more convenient dosing poses a meaningful commercial risk that could erode Revuforj market share.
Market Opportunity UncertaintyUncertainty around the total market opportunity and the pace of further Revuforj adoption creates downside risk to revenue and investor sentiment.
Spending And Cash Flow PressurePlanned elevated research, development, and selling expenses increase pressure on cash flow and hinge on successful clinical results to justify continued investment.
Syndax Pharmaceuticals News
SNDX FAQ
What was Syndax Pharmaceuticals Inc.’s price range in the past 12 months?
Syndax Pharmaceuticals Inc. lowest stock price was $8.58 and its highest was $22.73 in the past 12 months.
What is Syndax Pharmaceuticals Inc.’s market cap?
Syndax Pharmaceuticals Inc.’s market cap is $1.95B.
When is Syndax Pharmaceuticals Inc.’s upcoming earnings report date?
Syndax Pharmaceuticals Inc.’s upcoming earnings report date is May 11, 2026 which is in 63 days.
How were Syndax Pharmaceuticals Inc.’s earnings last quarter?
Syndax Pharmaceuticals Inc. released its earnings results on Feb 26, 2026. The company reported -$0.78 earnings per share for the quarter, missing the consensus estimate of -$0.584 by -$0.196.
Is Syndax Pharmaceuticals Inc. overvalued?
According to Wall Street analysts Syndax Pharmaceuticals Inc.’s price is currently Undervalued.
Does Syndax Pharmaceuticals Inc. pay dividends?
Syndax Pharmaceuticals Inc. does not currently pay dividends.
What is Syndax Pharmaceuticals Inc.’s EPS estimate?
Syndax Pharmaceuticals Inc.’s EPS estimate is -0.58.
How many shares outstanding does Syndax Pharmaceuticals Inc. have?
Syndax Pharmaceuticals Inc. has 88,200,600 shares outstanding.
What happened to Syndax Pharmaceuticals Inc.’s price movement after its last earnings report?
Syndax Pharmaceuticals Inc. reported an EPS of -$0.78 in its last earnings report, missing expectations of -$0.584. Following the earnings report the stock price went up 5.031%.
Which hedge fund is a major shareholder of Syndax Pharmaceuticals Inc.?
Currently, no hedge funds are holding shares in SNDX
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Syndax Pharmaceuticals Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$41.67 (88.81% Upside)
$41.67 (88.81% Upside)
Blogger Sentiment
Bullish
SNDX Sentiment 70%
Sector Average ―
Sector Average ―
Hedge Fund Trend
Decreased
By 299.9K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $628.1K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Negative
Last 7 Days ▼ 2.3%
Last 30 Days ▼ 6.8%
Last 30 Days ▼ 6.8%
News Sentiment
Very Bullish
Bullish news 99%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Positive
20 days / 200 days
Momentum
54.44%
12-Months-Change
Fundamentals
Return on Equity
-161.82%
Trailing 12-Months
Asset Growth
-26.92%
Trailing 12-Months
Company Description
Syndax Pharmaceuticals Inc.
Syndax Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops therapies for the treatment of cancer. Its lead product candidates are SNDX-5613, which is in phase 1/2 clinical trial targeting the binding interaction of Menin with the mixed lineage leukemia 1 protein for the treatment of MLL-rearranged (MLLr) and nucleophosmin 1 mutant acute myeloid leukemia (NPM1c AML); and SNDX-6352 or axatilimab, a monoclonal antibody that blocks the colony stimulating factor 1, or CSF-1 receptor for the treatment of patients with chronic graft versus host disease (cGVHD). The company is also developing Entinostat. It also has collaborative research and development agreement with National Cancer Institute; a clinical trial agreement with Eastern Cooperative Oncology Group; and a license agreement with Kyowa Hakko Kirin Co., Ltd. Syndax Pharmaceuticals, Inc. was incorporated in 2005 and is headquartered in Waltham, Massachusetts.Massachusetts.
SNDX Company Deck
SNDX Earnings Call
Q4 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call conveyed strong commercial momentum and meaningful scientific progress: two successful launches, accelerating quarter-over-quarter revenue growth (Revuforj +38% QoQ; Niktimvo +22% QoQ), solid real-world evidence, a healthy year-end cash balance ($394M) and multiple near- and mid-term clinical catalysts (frontline pivotal trials and an IPF readout). Offsetting factors include a high 2026 expense run-rate (~$400M), still-short average treatment duration in year one for Revuforj (4–6 months), incomplete post-transplant maintenance uptake (~40%–45%) and the risk that pending clinical readouts or competitive dynamics could temper expectations. On balance, highlights and growth drivers substantially outweigh near-term risks, but upcoming readouts and execution on duration/maintenance adoption and expense control are critical.View all SNDX earnings summariesSNDX Stock 12 Month Forecast
Average Price Target
$41.67
▲(88.81% Upside)
Technical Analysis
Ownership Overview
1.69% Insiders
14.58% Mutual Funds
12.30% Other Institutional Investors
56.82% Public Companies and Individual Investors